Xeris Biopharma (XERS) Short Interest Ratio & Short Volume

Xeris Biopharma logo
$16.77 +0.07 (+0.42%)
As of 01:33 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Xeris Biopharma Short Interest Overview

As of October 30, 2026, Xeris Biopharma (XERS) had a short interest of 8.99 million shares sold short, representing 5.14% of the public float. This marks an 11.95% increase in short interest since the prior report. The short interest ratio (days to cover) is 4.3, meaning it would take 4.3 days of the average trading volume of 2.14 million shares to cover all short positions.

Current Short Interest
8,986,870 shares
Previous Short Interest
8,027,654 shares
Change Vs. Previous Report
11.95%
Dollar Volume Sold Short
$96.25 million
Short Interest Ratio
4.3 Days to Cover
Last Record Date
October 30, 2026
Outstanding Shares
182,700,000 shares
Short Percent of Float
5.14%
Today's Trading Volume
889,330 shares
Average Trading Volume
2,142,839 shares
Today's Volume Vs. Average
42%
Short Selling Xeris Biopharma?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Xeris Biopharma and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History

XERS Short Interest Over Time

XERS Days to Cover Over Time

XERS Percentage of Float Shorted Over Time

Xeris Biopharma Tesla Short Interest History & Recent Changes

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
10/30/20268,986,870 shares $96.25 million +12.0%5.1%4.34 $10.71
10/15/20268,027,654 shares $80.84 million +11.5%4.6%3.26 $10.07
9/30/20267,202,379 shares $68.85 million -10.6%4.1%1.74 $9.56
9/15/20268,058,977 shares $60.36 million +0.2%4.6%4.83 $7.49
8/31/20268,041,258 shares $67.87 million -7.9%4.6%5.47 $8.44
8/14/20268,728,856 shares $75.07 million -5.3%5.0%4.44 $8.60
7/31/20269,221,405 shares $74.51 million -8.5%5.6%6.75 $8.08
7/15/202610,078,469 shares $87.68 million -21.0%6.1%4.38 $8.70
6/30/202612,760,034 shares $101.06 million -0.4%7.7%5.44 $7.92
6/15/202612,810,046 shares $88.13 million +2.4%7.8%7.33 $6.88
5/29/202612,514,253 shares $77.09 million +1.2%7.6%9.42 $6.16
5/15/202612,364,664 shares $77.16 million -22.2%7.7%5.8 $6.24
4/30/202615,894,656 shares $97.43 million +1.0%9.6%12.68 $6.13
4/15/202615,738,746 shares $97.58 million -4.1%9.5%11.01 $6.20
3/31/202616,412,903 shares $95.19 million +1.2%9.9%8.94 $5.80
3/13/202616,223,073 shares $88.58 million -4.7%9.9%6.77 $5.46
2/27/202617,015,319 shares $104.13 million -2.1%10.3%7.47 $6.12
2/13/202617,385,964 shares $118.57 million +2.3%10.5%13.89 $6.82
1/30/202616,996,095 shares $125.09 million +0.7%10.7%11.51 $7.36
1/15/202616,883,379 shares $125.11 million +2.2%10.7%6.04 $7.41
12/31/202516,522,754 shares $129.70 million +7.1%10.4%7.75 $7.85
12/15/202515,434,811 shares $108.82 million -3.4%9.7%6.93 $7.05
11/28/202515,974,039 shares $114.77 million +1.5%10.1%8.98 $7.19
11/14/202515,746,194 shares $113.06 million -10.7%9.9%4.01 $7.18
10/31/202517,626,897 shares $170.98 million -1.3%11.1%8.61 $9.70
10/15/202517,850,000 shares $165.47 million +2.4%11.6%7.1 $9.27
9/30/202517,440,000 shares $141.96 million +7.4%N/A7.3 $8.14
9/15/202516,240,000 shares $119.53 million +10.4%N/A6.7 $7.36
8/31/202514,710,000 shares $115.18 million +10.2%9.7%6.2 $7.83
8/15/202513,350,000 shares $102.53 million -26.7%N/A5.4 $7.68
7/31/202518,220,000 shares $92.74 million -6.8%12.1%7.4 $5.09
7/15/202519,550,000 shares $103.42 million +164.6%N/A9.1 $5.29
6/30/20257,390,000 shares $34.51 million -58.8%5.1%5.8 $4.67
6/15/202517,940,000 shares $78.04 million +1.9%12.3%6.9 $4.35
5/31/202517,600,000 shares $86.77 million -1.1%12.4%5.8 $4.93
5/15/202517,800,000 shares $85.26 million +3.3%12.5%5.8 $4.79
4/30/202517,230,000 shares $78.74 million -9.6%N/A5.6 $4.57
4/15/202519,050,000 shares $83.44 million +11.8%13.4%6.5 $4.38
3/31/202517,040,000 shares $93.55 million +52.0%12.0%6.1 $5.49
3/15/202511,210,000 shares $54.03 million +5.5%7.9%4.8 $4.82
The investigation Porter spent tens of thousands to document (Ad)

Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel

Watch the full investigation and decide for yourself
2/28/202510,630,000 shares $40.71 million +3.5%7.5%5.5 $3.83
2/15/202510,270,000 shares $36.87 million -2.1%7.2%6.3 $3.59
1/31/202510,490,000 shares $37.34 million +1.3%N/A6.2 $3.56
1/15/202510,360,000 shares $33.57 million +1.7%N/A6.3 $3.24
12/31/202410,190,000 shares $34.54 million +7.0%N/A6.4 $3.39
12/15/20249,520,000 shares $31.23 million -3.9%N/A6.1 $3.28
11/30/20249,910,000 shares $32.50 million -2.4%N/A6.1 $3.28
11/15/202410,150,000 shares $29.64 million -10.7%N/A6.4 $2.92
10/31/202411,370,000 shares $36.61 million -1.7%N/A7.2 $3.22
10/15/202411,570,000 shares $34.94 million +4.3%N/A7.7 $3.02
9/30/202411,090,000 shares $31.61 million +0.8%N/A7.2 $2.85
9/15/202411,000,000 shares $31.68 million +2.7%N/A7.1 $2.88
8/31/202410,710,000 shares $30.10 million -0.9%N/A7.6 $2.81
8/15/202410,810,000 shares $28.32 million -3.7%N/A7.5 $2.62
7/31/202411,220,000 shares $27.83 million -1.7%N/A7.9 $2.48
7/15/202411,410,000 shares $28.30 million +3.7%N/A8.7 $2.48
6/30/202411,000,000 shares $24.75 million -0.8%N/A8.2 $2.25
6/15/202411,088,000 shares $24.39 million -2.1%N/A7.9 $2.20
5/31/202411,330,000 shares $25.55 million +5.0%N/A7.3 $2.26
5/15/202410,790,000 shares $21.36 million +11.9%N/A6.4 $1.98
4/30/20249,640,000 shares $16.87 million +7.8%N/A5.2 $1.75
4/15/20248,940,000 shares $16.54 million -0.5%N/A4.8 $1.85
3/31/20248,980,000 shares $19.85 million -2.8%N/A4 $2.21
3/15/20249,240,000 shares $20.61 million -4.2%N/A4 $2.23
2/29/20249,640,000 shares $29.64 million +2.3%N/A4.2 $3.08
2/15/20249,420,000 shares $30.24 million +0.2%N/A4.6 $3.21
1/31/20249,400,000 shares $23.12 million -9.7%N/A4.7 $2.46
1/15/202410,410,000 shares $28.84 million +8.3%N/A5.5 $2.77
12/31/20239,610,000 shares $22.58 million +18.4%N/A6.6 $2.35
12/15/20238,120,000 shares $16.40 million -1.2%N/A6.2 $2.02
11/30/20238,220,000 shares $15.29 million -8.2%N/A7 $1.86
11/15/20238,950,000 shares $13.16 million +14.9%N/A8.1 $1.47
10/31/20237,790,000 shares $14.26 million +2.4%N/A8.4 $1.83
10/15/20237,610,000 shares $12.02 million -4.0%N/A8 $1.58
9/30/20237,930,000 shares $14.75 million +0.6%N/A8.4 $1.86
9/15/20237,880,000 shares $15.76 million +6.2%N/A7.5 $2.00
8/31/20237,420,000 shares $16.84 million -12.9%N/A6.9 $2.27
8/15/20238,520,000 shares $19.00 million +2.7%N/A7.8 $2.23
7/31/20238,300,000 shares $21.66 million -2.6%N/A7.1 $2.61
7/15/20238,520,000 shares $21.64 million +0.4%N/A7.2 $2.54
6/30/20238,490,000 shares $22.24 million -5.0%N/A6.5 $2.62
6/15/20238,940,000 shares $24.23 million +13.6%N/A6.7 $2.71
5/31/20237,870,000 shares $20.15 million -5.5%N/A6.2 $2.56
5/15/20238,330,000 shares $23.66 million -1.9%N/A6.3 $2.84
4/30/20238,490,000 shares $19.19 million +6.3%N/A6.9 $2.26
4/15/20237,990,000 shares $17.34 million +2.0%N/A7 $2.17
3/31/20237,830,000 shares $12.76 million -5.4%N/A6.7 $1.63
3/15/20238,280,000 shares $10.76 million +20.9%N/A7.6 $1.30
2/28/20236,850,000 shares $9.45 million +13.4%N/A6.9 $1.38
2/15/20236,040,000 shares $7.61 million -6.9%N/A6.8 $1.26
I'm handing you this stock today (Ad)

Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel

Download this free stock pick before December 8th arrives
1/31/20236,490,000 shares $8.05 million +9.1%N/A7.7 $1.24
1/15/20235,950,000 shares $7.62 million +1.9%N/A6.8 $1.28
12/30/20225,840,000 shares $7.77 million +2.5%N/A6.5 $1.33
12/15/20225,700,000 shares $7.64 million -0.7%N/A7.3 $1.34
11/30/20225,740,000 shares $8.61 million -9.5%N/A7 $1.50
11/15/20226,340,000 shares $8.81 million +0.8%N/A7.7 $1.39
10/31/20226,290,000 shares $10.06 million +0.8%N/A7.6 $1.60
10/15/20226,240,000 shares $7.61 million -5.5%N/A7.2 $1.22
9/30/20226,600,000 shares $10.30 million -21.6%N/A8 $1.56
9/15/20228,420,000 shares $15.07 million -8.1%N/A8 $1.79
8/31/20229,160,000 shares $15.30 million -4.8%N/A8.3 $1.67
8/15/20229,620,000 shares $18.18 million -7.1%N/A7.5 $1.89
7/31/202210,350,000 shares $14.70 million +4.9%N/A6.1 $1.42
7/15/20229,870,000 shares $14.11 million -3.3%N/A5.5 $1.43
6/30/202210,210,000 shares $15.72 million +64.7%N/A5.6 $1.54
6/15/20226,200,000 shares $10.91 million -8.3%N/A3.3 $1.76
5/31/20226,760,000 shares $14.94 million +9.0%N/A3.7 $2.21
5/15/20226,200,000 shares $10.60 million +14.6%N/A3.4 $1.71
4/30/20225,410,000 shares $13.20 million +20.2%N/A3.3 $2.44
4/15/20224,500,000 shares $11.03 million +12.8%N/A2.6 $2.45
3/31/20223,990,000 shares $10.21 million -23.4%N/A2.1 $2.56
3/15/20225,210,000 shares $13.91 million -1.7%N/A1.7 $2.67
2/28/20225,300,000 shares $12.61 million -17.3%N/A1.8 $2.38
2/15/20226,410,000 shares $16.47 million -3.5%N/A2.1 $2.57
1/31/20226,640,000 shares $14.01 million +41.6%N/A2.1 $2.11
1/15/20224,690,000 shares $10.41 million +27.5%N/A1.5 $2.22
12/31/20213,680,000 shares $10.78 million +4.3%N/A0 $2.93
12/15/20213,530,000 shares $8.01 million +16.1%N/A1.9 $2.27
11/30/20213,040,000 shares $6.35 million -30.9%N/A1.8 $2.09

XERS Short Interest - Frequently Asked Questions

Short interest is the volume of Xeris Biopharma shares that have been sold short but have not yet been closed out or covered. As of October 30th, investors have sold 8,986,870 shares of XERS short. 5.14% of Xeris Biopharma's shares are currently sold short. Learn More on Xeris Biopharma's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. XERS shares currently have a short interest ratio of 4.3. Learn More on Xeris Biopharma's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.14% of Xeris Biopharma's floating shares are currently sold short.

Xeris Biopharma saw an increase in short interest since the prior report. As of October 30th, there was short interest totaling 8,986,870 shares, an increase of 11.9% from the previous total of 8,027,654 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

5.14% of Xeris Biopharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceuticals" compare to Xeris Biopharma: Corcept Therapeutics Incorporated (10.51%), Axsome Therapeutics, Inc. (7.81%), Amneal Pharmaceuticals, Inc. (4.31%), Lantheus Holdings, Inc. (5.67%), Belite Bio, Inc. Sponsored ADR (3.95%), Veradermics, Incorporated (8.11%), Definium Therapeutics, Inc. (7.33%), Liquidia Corporation (26.30%), Organon & Co. (7.62%), Tarsus Pharmaceuticals, Inc. (13.62%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($77.66 billion), Invesco QQQ ($57.17 billion), iShares Russell 2000 ETF ($21.91 billion), SPDR S&P Biotech ETF ($10.53 billion), Union Pacific Corporation ($9.26 billion), iShares iBoxx $ High Yield Corporate Bond ETF ($9.05 billion), Nebius Group N.V. ($7.85 billion), iShares 20+ Year Treasury Bond ETF ($7.81 billion), Moderna, Inc. ($7.36 billion), and iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.20 billion). View all of the most shorted stocks.

Short selling XERS is an investing strategy that aims to generate trading profit from Xeris Biopharma as its price is falling. XERS shares are trading up $0.10 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Xeris Biopharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of XERS, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including XERS, twice per month. The most recent reporting period available is October, 30 2026.

Understanding short interest metrics can help you assess how traders are positioning around a stock like XERS:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.



Short interest data for NASDAQ:XERS is sourced from the Financial Industry Regulatory Authority (FINRA), with the most recent report published on 11/10/2026. FINRA publishes updated short interest twice a month.
From Our Partners